Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
BioMarin to hold a virtual meeting » 10:55
11/30/21
11/30
10:55
11/30/21
10:55
BMRN

BioMarin

$87.00 /

-0.42 (-0.48%)

Virtual Research &…

Virtual Research & Development Day 2021 to be held on November 30 at 11 am. Webcast Link

ShowHide Related Items >><<
BMRN BioMarin
$87.00 /

-0.42 (-0.48%)

BMRN BioMarin
$87.00 /

-0.42 (-0.48%)

11/23/21 Baird
BioMarin price target raised to $112 from $101 at Baird
11/22/21 Oppenheimer
BioMarin price target raised to $95 from $84 at Oppenheimer
11/22/21 Credit Suisse
BioMarin price target raised to $105 from $100 at Credit Suisse
11/22/21 JPMorgan
BioMarin price target raised to $135 from $129 at JPMorgan
BMRN BioMarin
$87.00 /

-0.42 (-0.48%)

BMRN BioMarin
$87.00 /

-0.42 (-0.48%)

Conference/Events
BioMarin to hold a virtual meeting » 04:55
11/30/21
11/30
04:55
11/30/21
04:55
BMRN

BioMarin

$87.39 /

-0.255 (-0.29%)

Virtual Research &…

Virtual Research & Development Day 2021 to be held on November 30 at 11 am. Webcast Link

ShowHide Related Items >><<
BMRN BioMarin
$87.39 /

-0.255 (-0.29%)

BMRN BioMarin
$87.39 /

-0.255 (-0.29%)

11/23/21 Baird
BioMarin price target raised to $112 from $101 at Baird
11/22/21 Oppenheimer
BioMarin price target raised to $95 from $84 at Oppenheimer
11/22/21 Credit Suisse
BioMarin price target raised to $105 from $100 at Credit Suisse
11/22/21 JPMorgan
BioMarin price target raised to $135 from $129 at JPMorgan
BMRN BioMarin
$87.39 /

-0.255 (-0.29%)

BMRN BioMarin
$87.39 /

-0.255 (-0.29%)

Conference/Events
BioMarin to hold a virtual meeting » 16:46
11/24/21
11/24
16:46
11/24/21
16:46
BMRN

BioMarin

$89.62 /

-0.14 (-0.16%)

Virtual Research &…

Virtual Research & Development Day 2021 to be held on November 30 at 11 am. Webcast Link

ShowHide Related Items >><<
BMRN BioMarin
$89.62 /

-0.14 (-0.16%)

BMRN BioMarin
$89.62 /

-0.14 (-0.16%)

11/23/21 Baird
BioMarin price target raised to $112 from $101 at Baird
11/22/21 Oppenheimer
BioMarin price target raised to $95 from $84 at Oppenheimer
11/22/21 Credit Suisse
BioMarin price target raised to $105 from $100 at Credit Suisse
11/22/21 JPMorgan
BioMarin price target raised to $135 from $129 at JPMorgan
BMRN BioMarin
$89.62 /

-0.14 (-0.16%)

BMRN BioMarin
$89.62 /

-0.14 (-0.16%)

Recommendations
BioMarin price target raised to $112 from $101 at Baird » 06:55
11/23/21
11/23
06:55
11/23/21
06:55
BMRN

BioMarin

/

+

Baird analyst Joel Beatty…

Baird analyst Joel Beatty raised the firm's price target on BioMarin to $112 from $101 and keeps an Outperform rating on the shares. The analyst cited the FDA approval of Voxzogo which he said gives the company a meaningful new approved treatment, and should also improve sentiment on the stock.

ShowHide Related Items >><<
BMRN BioMarin
/

+

BMRN BioMarin
/

+

11/22/21 Oppenheimer
BioMarin price target raised to $95 from $84 at Oppenheimer
11/22/21 Credit Suisse
BioMarin price target raised to $105 from $100 at Credit Suisse
11/22/21 JPMorgan
BioMarin price target raised to $135 from $129 at JPMorgan
11/22/21 William Blair
BioMarin upgraded to Outperform from Market Perform at William Blair
BMRN BioMarin
/

+

BMRN BioMarin
/

+

Recommendations
BioMarin price target raised to $95 from $84 at Oppenheimer » 09:36
11/22/21
11/22
09:36
11/22/21
09:36
BMRN

BioMarin

$91.50 /

+8.64 (+10.43%)

Oppenheimer analyst…

Oppenheimer analyst Leland Gershell raised the firm's price target on BioMarin to $95 from $84 and keeps a Perform rating on the shares after the FDA granted accelerated approval to Voxzogo for the treatment of achondroplasia in people greater than or equal to five years of age, a restriction that comes in line with expectations. The label presented no surprises, the analyst contends, noting that the product will become available by the end of the year.

ShowHide Related Items >><<
BMRN BioMarin
$91.50 /

+8.64 (+10.43%)

BMRN BioMarin
$91.50 /

+8.64 (+10.43%)

11/22/21 Credit Suisse
BioMarin price target raised to $105 from $100 at Credit Suisse
11/22/21 JPMorgan
BioMarin price target raised to $135 from $129 at JPMorgan
11/22/21 William Blair
BioMarin upgraded to Outperform from Market Perform at William Blair
11/19/21 Piper Sandler
Piper remains buyer of BioMarin, says Voxzogo approval wasn't '100% expected'
BMRN BioMarin
$91.50 /

+8.64 (+10.43%)

BMRN BioMarin
$91.50 /

+8.64 (+10.43%)

Recommendations
BioMarin price target raised to $105 from $100 at Credit Suisse » 08:10
11/22/21
11/22
08:10
11/22/21
08:10
BMRN

BioMarin

$91.50 /

+8.64 (+10.43%)

Credit Suisse analyst…

Credit Suisse analyst Tiago Fauth raised the firm's price target on BioMarin to $105 from $100 and keeps an Outperform rating on the shares following the FDA's approval VOXZOGO for the treatment of achondroplasia, the most common form of dwarfism, in children aged 5 years and up. The decision for accelerated approval is based on VOXZOGO's observed benefit in annualized growth velocity, in which VOXZOGO demonstrated a 1.57cm AGV improvement relative to placebo, the analyst contends, adding that full approval is contingent on postmarketing requirements evaluating achondroplasia patients treated with VOXZOGO through final adult height, which BioMarin expects will be adequately satisfied with its ongoing open label extension studies.

ShowHide Related Items >><<
BMRN BioMarin
$91.50 /

+8.64 (+10.43%)

BMRN BioMarin
$91.50 /

+8.64 (+10.43%)

11/22/21 JPMorgan
BioMarin price target raised to $135 from $129 at JPMorgan
11/22/21 William Blair
BioMarin upgraded to Outperform from Market Perform at William Blair
11/19/21 Piper Sandler
Piper remains buyer of BioMarin, says Voxzogo approval wasn't '100% expected'
11/19/21 Guggenheim
BioMarin price target raised to $120 from $103 at Guggenheim
BMRN BioMarin
$91.50 /

+8.64 (+10.43%)

BMRN BioMarin
$91.50 /

+8.64 (+10.43%)

Recommendations
BioMarin price target raised to $135 from $129 at JPMorgan » 07:44
11/22/21
11/22
07:44
11/22/21
07:44
BMRN

BioMarin

$91.50 /

+8.64 (+10.43%)

JPMorgan analyst Cory…

JPMorgan analyst Cory Kasimov raised the firm's price target on BioMarin to $135 from $129 and keeps an Overweight rating on the shares. BioMarin's U.S. Voxzogo approval "meaningfully de-risks the story" and adds to the company's base business value, Kasimov tells investors in a research note. The analyst believes the stock's risk/reward "still appears very attractive" even with Friday's rally.

ShowHide Related Items >><<
BMRN BioMarin
$91.50 /

+8.64 (+10.43%)

BMRN BioMarin
$91.50 /

+8.64 (+10.43%)

11/22/21 William Blair
BioMarin upgraded to Outperform from Market Perform at William Blair
11/19/21 Piper Sandler
Piper remains buyer of BioMarin, says Voxzogo approval wasn't '100% expected'
11/19/21 Guggenheim
BioMarin price target raised to $120 from $103 at Guggenheim
11/19/21 Stifel
Voxogo approval an 'important win' for BioMarin, says Stifel
BMRN BioMarin
$91.50 /

+8.64 (+10.43%)

BMRN BioMarin
$91.50 /

+8.64 (+10.43%)

Upgrade
BioMarin upgraded to Outperform from Market Perform at William Blair » 05:28
11/22/21
11/22
05:28
11/22/21
05:28
BMRN

BioMarin

$91.50 /

+8.64 (+10.43%)

William Blair analyst Tim…

William Blair analyst Tim Lugo upgraded BioMarin to Outperform from Market Perform without a price target after the FDA granted conditional approval to Voxzogo. The global total addressable market for Voxzogo may be $3B, assuming label expansions to patients under age five in U.S. and achieving reimbursement and access in other major markets, Lugo tells investors in a research note. He believes the approval is a clear growth driver and potentially the biggest launch and product for BioMarin to date. The focus will now shift back to Roctavian, with potential submissions in U.S. and Europe in the first half of 2022, Lugo says.

ShowHide Related Items >><<
BMRN BioMarin
$91.50 /

+8.64 (+10.43%)

BMRN BioMarin
$91.50 /

+8.64 (+10.43%)

11/19/21 Piper Sandler
Piper remains buyer of BioMarin, says Voxzogo approval wasn't '100% expected'
11/19/21 Guggenheim
BioMarin price target raised to $120 from $103 at Guggenheim
11/19/21 Stifel
Voxogo approval an 'important win' for BioMarin, says Stifel
10/27/21 Piper Sandler
BioMarin price target raised to $121 from $119 at Piper Sandler
BMRN BioMarin
$91.50 /

+8.64 (+10.43%)

BMRN BioMarin
$91.50 /

+8.64 (+10.43%)

Recommendations
Piper remains buyer of BioMarin, says Voxzogo approval wasn't '100% expected' » 11:47
11/19/21
11/19
11:47
11/19/21
11:47
BMRN

BioMarin

$89.43 /

+6.57 (+7.93%)

Piper Sandler analyst…

Piper Sandler analyst Christopher Raymond noted that Voxzogo being approved by the FDA in children five years and older with achondroplasia came by the November 20 PDUFA date, but given the FDA's "recent unpredictability" and BioMarin's "own experience in that regard," he argues that the approval "was not 100% expected." The label is "right down the middle of the fairway" given that management has telegraphed that U.S. labeling would be for five and older, said Raymond. The analyst, who thinks this approval "finally unlocks" Biomarin's next growth inflection and would remain a buyer here, has an Overweight rating and $121 price target on the shares.

ShowHide Related Items >><<
BMRN BioMarin
$89.43 /

+6.57 (+7.93%)

BMRN BioMarin
$89.43 /

+6.57 (+7.93%)

11/19/21 Guggenheim
BioMarin price target raised to $120 from $103 at Guggenheim
11/19/21 Stifel
Voxogo approval an 'important win' for BioMarin, says Stifel
10/27/21 Piper Sandler
BioMarin price target raised to $121 from $119 at Piper Sandler
10/15/21 JPMorgan
JPMorgan sees 'valuation disconnect' in shares of BioMarin
BMRN BioMarin
$89.43 /

+6.57 (+7.93%)

BMRN BioMarin
$89.43 /

+6.57 (+7.93%)

Recommendations
BioMarin price target raised to $120 from $103 at Guggenheim » 11:35
11/19/21
11/19
11:35
11/19/21
11:35
BMRN

BioMarin

$88.46 /

+5.595 (+6.75%)

Guggenheim analyst Debjit…

Guggenheim analyst Debjit Chattopadhyay raised the firm's price target on BioMarin to $120 from $103 and keeps a Buy rating on the shares after Voxzogo was approved in children 5 and older with achondroplasia and open growth plates. Voxzogo's label including decreased blood pressure as a safety warning is not a surprise and "a non-factor," said Chattopadhyay, who has a 2026 global sales estimate of $1.23B versus what he identifies as the $683M consensus forecast. His model of about 13,000 patients in the U.S., EU and rest of the world "could be conservative" given Biomarin's internal estimates of 25,000 in its commercial territories, the analyst added.

ShowHide Related Items >><<
BMRN BioMarin
$88.46 /

+5.595 (+6.75%)

BMRN BioMarin
$88.46 /

+5.595 (+6.75%)

11/19/21 Stifel
Voxogo approval an 'important win' for BioMarin, says Stifel
10/27/21 Piper Sandler
BioMarin price target raised to $121 from $119 at Piper Sandler
10/15/21 JPMorgan
JPMorgan sees 'valuation disconnect' in shares of BioMarin
10/06/21 Jefferies
BioMarin assumed with a Buy at Jefferies
BMRN BioMarin
$88.46 /

+5.595 (+6.75%)

BMRN BioMarin
$88.46 /

+5.595 (+6.75%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.